Locally Advanced or Metastatic Urothelial Carcinoma (UC) (DBCOND0123651)

Identifiers

Synonyms

Locally Advanced or Metastatic Urothelial Carcinoma

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Enfortumab vedotin	An antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer.	Cytochrome P450 3A4enzyme Nectin-4target ATP-dependent translocase ABCB1transporter
Erdafitinib	A fibroblast growth factor receptor tyrosine kinase inhibitor used to treat locally advanced or metastatic urothelial carcinoma.	Cytochrome P450 2C9enzyme Cytochrome P450 3A4enzyme Fibroblast growth factor receptor 1target Fibroblast growth factor receptor 2target Fibroblast growth factor receptor 3target Fibroblast growth factor receptor 4target ATP-dependent translocase ABCB1transporter Solute carrier family 22 member 2transporter Proto-oncogene tyrosine-protein kinase receptor Rettarget Macrophage colony-stimulating factor 1 receptortarget Platelet-derived growth factor receptor alphatarget Platelet-derived growth factor receptor betatarget Mast/stem cell growth factor receptor Kittarget Vascular endothelial growth factor receptor 2target alpha1-acid glycoproteincarrier
Pembrolizumab	A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.	Programmed cell death protein 1target Programmed cell death 1 ligand 1target
Sacituzumab govitecan	Sacituzumab govitecan targets TROP-2-expressing cancer cells through a humanized antibody (RS7) before subsequently becoming internalized and releasing the topoisomerase I inhibitor SN-38 to induce DNA damage-mediated apoptosis.	Tumor-associated calcium signal transducer 2target DNA topoisomerase 1target Far upstream element-binding protein 1target UDP-glucuronosyltransferase 1A1enzyme

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04602078	Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma	Atezolizumab Cisplatin Gemcitabine	treatment	2	completed
NCT05327530	A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)	Avelumab Sacituzumab govitecan	treatment	2	active_not_recruiting
NCT04568304	A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma	Carboplatin Cisplatin Gemcitabine Toripalimab	treatment	3	not_yet_recruiting
NCT04136808	An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma	Enfortumab vedotin	Not Available	Not Available	approved_for_marketing